Somatic mutations in the epidermal growth factor receptor (EGFR) gene are present in
approximately 20%(in Caucasians) to 40%(in East Asians) of adenocarcinomas of the lung …

Despite tremendous progress in the last decade, lung adenocarcinoma still represents a
tumor with unfavorable prognosis when detected at advanced clinical stage. High-stage …

Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …

Backgrounds It has been extensively proved that the efficacy of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC)
driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain …

Lung cancers with a mutated epidermal growth factor receptor (EGFR) are a major
contributor to cancer fatalities globally. Targeted tyrosine kinase inhibitors (TKIs) have been …

Ten years ago, somatic mutations in EGFR were identified in patients with non-small-cell
lung cancer. Demonstration of the antitumor efficacy of EGF receptor-directed tyrosine …

Abstract Background Although EGFR-TKI is the preferred treatment for NSCLC patients with
sensitive mutations, subsequent drug resistance is almost inevitable. The specific …

The recent development of imaging and sequencing technologies enables systematic
advances in the clinical study of lung cancer. Meanwhile, the human mind is limited in …

Purpose Exon 19 deletion and exon 21 L858R mutation were the most common epidermal
growth factor receptor (EGFR) mutations. We examined the clinical impact of these two …